Sirnaomics has a robust pipeline of biopharmaceutical therapies built through the in-house development of innovative product candidates and novel RNAi and mRNA delivery platforms, becoming the first company to achieve positive Phase Ⅱ clinical outcomes in oncology for an RNAi therapeutic.
We have 19 therapeutic candidates in the preclinical stage through Phase Ⅱ clinical trials in the U.S. and China, addressing a wide range of disease areas, from oncology and fibrotic disease, to cardiometabolic, viral and liver disease.
We focus on developing new delivery platforms for RNA therapeutics, which include:
- PNP delivery platform for local or systemic administration of RNAi therapeutics,
- GalNAc-RNAi delivery platform for administration of RNAi therapeutics to the liver,
- Peptide docking vehicle (PDOV) platform for improved delivery and release of siRNAs into the hepatocytes in the liver;
- PLNP delivery platform for administration of mRNA vaccines and therapeutics.
Drug Delivery Systems
Our highly innovative RNA delivery platforms distinguish Sirnaomics from other drug development companies. Delivery platforms are critical to the intact delivery of RNA therapeutics to the cells where they are needed. Our proprietary PNP and novel GalNAc delivery platforms provide advantages over conventional delivery platforms.